Jeffrey S. Heier (Chief Scientific Officer) sold ~$77K of Ocular Therapeutix
Automatic saleLoading…
OCUL · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Bedford, Ma.
In the last 90 days, no insider of Ocular Therapeutix reported an open-market purchase and 2 open-market sales worth about $147K. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$7.34
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 29.9M shares sold short, +6.7% vs the previous count, 14.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$13.5M
+0.1% vs the same quarter a year earlier
Free cash flow, last 12 months
−$255M
This quarter −$70.6M, a year earlier −$56.5M
Net debt
—
Debt —, cash $599M, at Jun 30, 2026
Net income, last 12 months
−$301M
Operating profit covers interest -27.5x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 3, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$147K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Fails to deliver: 98K shares (about $1.04M) were not delivered on time for settlement on Sep 2, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
4 active phase 3 trials and 0 active phase 2 trials led by this company, mostly in neovascular age-related macular degeneration, neovascular age-related macular degeneration, non-proliferative diabetic retinopathy. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.